Acquired Thrombotic Thrombocytopenic Purpura
Also known as: Acquired Thrombotic Thrombocytopenic Purpura (aTTP) / Acquired thrombotic thrombocytopenic purpura (disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB06081 | Caplacizumab | A von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP). |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB06081 | Caplacizumab | von Willebrand factor | target |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB15094 | Anfibatide | 2 | Unknown Status | 1 |
| DB15164 | Apadamtase alfa | 2 | Completed | 1 |
| DB06081 | Caplacizumab | 2 | Completed | 1 |
| DB06081 | Caplacizumab | 2 | Not Yet Recruiting | 1 |
| DB06081 | Caplacizumab | 3 | Completed | 2 |
| DB00188 | Bortezomib | 4 | Not Yet Recruiting | 1 |
| DB06081 | Caplacizumab | Not Available | Recruiting | 2 |